BioWorld

April 5, 2010

Sequencing Speeds Up, But Drug Discovery Still a Slog

Biotech's Future: BioWorld Gives You 2020 Vision in 2010!

Salix Liver-Failure Win Puts Spotlight on Xifaxan in IBS

Salix Pharmaceuticals Inc.'s path forward should become clear shortly with the approved antibiotic Xifaxan in its third potential, and much-coveted, indication: irritable bowel syndrome. (BioWorld Today) Read More

New NYU Stem Cell Lines Boost NIH Registry to 51

Today's news in brief

BioWorld

ADPD 2026: Can we prevent dementia? Scientists quantify it

BioWorld

Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...

Illustration of Alzheimer's disease in the brain

ADPD 2026: Three inflection points to target Alzheimer’s disease

BioWorld Science

A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...

Emerging therapeutic strategies for Parkinson’s at ADPD 2026

BioWorld

Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 24, 2026

BioWorld

April 5, 2010

Sequencing Speeds Up, But Drug Discovery Still a Slog

Biotech's Future: BioWorld Gives You 2020 Vision in 2010!

Appointments And Advancements

Vital Signs

Other News To Note

Financings Roundup

Clinic Roundup

Bench Press

Salix Liver-Failure Win Puts Spotlight on Xifaxan in IBS

New NYU Stem Cell Lines Boost NIH Registry to 51

Today's news in brief

ADPD 2026: Can we prevent dementia? Scientists quantify it

ADPD 2026: Three inflection points to target Alzheimer’s disease

Emerging therapeutic strategies for Parkinson’s at ADPD 2026

News in brief